Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR2001 vs HTIG for Tetanus Prophylaxis
NCT06635798Phase 3Recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Sep 2024
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of vecantoxatug in Tetanus, sponsored by Zhixiang Jintai. Started Sep 2024; status: recruiting.
02
Drugs
vecantoxatug
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT06635798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06635798.